Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry

Journal of Immunological Methods

Volumn 368, Issue 1-2, 2011, Pages 54-63

  Helguera, Gustavo ^a,b   Rodríguez, José A ^a,c   Luria Pérez, Rosendo ^a,d   Henery, Shannon ^e   Catterton, Paul ^e   Bregni, Carlos ^b   George, Thaddeus C ^e   Martínez Maza, Otoniel ^a   Penichet, Manuel L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Children's Hospital of Mexico Federico Gomez   (Mexico)

^e Amnis Corporation   (United States)

Author keywords

ADCC; Antibody; Cancer; Imaging flow cytometry; Immunotherapy

Indexed keywords

RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CELL INTERACTION; CONTROLLED STUDY; DRUG SCREENING; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; TARGET CELL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; FLOW CYTOMETRY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; U937 CELLS;

EID: 79955475889     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2011.03.003     Document Type: Article

References (25)

1. Beum P.V., Lindorfer M.A., Hall B.E., George T.C., Frost K., Morrissey P.J., Taylor R.P. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J. Immunol. Methods 2006, 317:90.
2. Beum P.V., Mack D.A., Pawluzkowczkowycz A.W., Lindorfer M.A., Taylor R.P. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by thp-1 cells and monocytes. J. Immunol. 2008, 181:8120.
3. Brunner K.T., Mauel J., Cerottini J.C., Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968, 14:181.
4. Cohen J.J. Apoptosis. Immunol. Today 1993, 14:126.
5. Dalle S., Thieblemont C., Thomas L., Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med. Chem. 2008, 8:523.
6. Ferris R.L., Jaffee E.M., Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, 28:4390.
7. George T.C., Basiji D.A., Hall B.E., Lynch D.H., Ortyn W.E., Perry D.J., Seo M.J., Zimmerman C.A., Morrissey P.J. Distinguishing modes of cell death using the ImageStream multispectral imaging flow cytometer. Cytometry A 2004, 59:237.
8. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823.
9. Hashimoto G., Wright P.F., Karzon D.T. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 1983, 148:785.
10. Henery S., George T., Hall B., Basiji D., Ortyn W., Morrissey P. Quantitative image based apoptotic index measurement using multispectral imaging flow cytometry: a comparison with standard photometric methods. Apoptosis 2008, 13:1054.
11. Horner H., Frank C., Dechant C., Repp R., Glennie M., Herrmann M., Bernhard Stockmeyer B. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J. Immunol. 2007, 179:337.
12. 111indium-oxine-labelled targets. J. Immunol. Methods 1983, 60:379.
13. Jazirehi A.R., Vega M.I., Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007, 67:1270.
14. Karagiannis S.N., Bracher M.G., Hunt J., McCloskey N., Beavil R.L., Beavil A.J., Fear D.J., Thompson R.G., East N., Burke F., Moore R.J., Dombrowicz D.D., Balkwill F.R., Gould H.J. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J. Immunol. 2007, 179:2832.
15. Kim G.G., Donnenberg V.S., Donnenberg A.D., Gooding W., Whiteside T.L. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4h 51Cr-release assay. J. Immunol. Methods 2007, 325:51.
16. Leidi M., Gotti E., Bologna L., Miranda E., Rimoldi M., Sica A., Roncalli M., Palumbo G.A., Introna M., Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J. Immunol. 2009, 182:4415.
17. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949.
18. Megjugorac N.J., Jacobs E.S., Izaguirre A.G., George T.C., Gupta G., Fitzgerald-Bocarsly P. Image-based study of interferongenic interactions between plasmacytoid dendritic cells and HSV-infected monocyte-derived dendritic cells. Immunol. Invest. 2007, 36:739.
19. Metelitsa L.S., Gillies S.D., Super M., Shimada H., Reynolds C.P., Seeger R.C. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002, 99(11):4166.
20. Moore T., Ananaba G.A., Bolier J., Bowers S., Belay T., Eko F.O., Igietseme J.U. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002, 105:213.
21. Stockmeyer B.V.T., Repp R., Deo Y., van de Winkel J.G.J., Kalden J.R., Gramatzki M. Cell adhesion molecules cooperate with Fc-{gamma}-RI in ADCC of G-CSF primed neutrophils against breast cancer cells. Blood 1996, 88.
22. Stockmeyer B., Beyer T., Neuhuber W., Repp R., Kalden J.R., Valerius T., Herrmann M. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J. Immunol. 2003, 171:5124.
23. Taylor R.J., Chan S.L., Wood A., Voskens C.J., Wolf J.S., Lin W., Chapoval A., Schulze D.H., Tian G., Strome S.E. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2009, 58:997.
24. Wang S.Y., Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin. Biol. Ther. 2008, 8:759.
25. Wisecarver J., Bechtold T., Collins M., Davis J., Lipscomb H., Sonnabend J., Purtilo D.T. A method for determination of antibody-dependent cellular cytotoxicity (ADCC) of human peripheral mononuclear cells. J. Immunol. Methods 1985, 79:277.